Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 184

Results For "drug"

3417 News Found

Multiple sclerosis market to generate sales of $29.8 billion by 2030, forecasts GlobalData
News | April 19, 2023

Multiple sclerosis market to generate sales of $29.8 billion by 2030, forecasts GlobalData

Several late-stage pipeline products have the potential to address some of these unmet needs


Zydus receives final approval from the USFDA for Estradiol Transdermal System
Drug Approval | April 19, 2023

Zydus receives final approval from the USFDA for Estradiol Transdermal System

Estradiol Transdermal System USP, 0.014 mg/day (weekly) had annual sales of USD 1.9 mn in the United States


Everest Medicines partners with Shanghai Pharma Subsidiary to accelerate the commercialization of XERAVA in Mainland China
News | April 19, 2023

Everest Medicines partners with Shanghai Pharma Subsidiary to accelerate the commercialization of XERAVA in Mainland China

Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA in China


Ascentage presents results of studies underscoring exploratory efforts in potential
Clinical Trials | April 18, 2023

Ascentage presents results of studies underscoring exploratory efforts in potential

The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications


Zydus receives final approval from the USFDA for Isoproterenol Hydrochloride Injection
Drug Approval | April 17, 2023

Zydus receives final approval from the USFDA for Isoproterenol Hydrochloride Injection

Isoproterenol hydrochloride injection is indicated to improve hemodynamic status in patients in distributive shock and shock due to reduced cardiac output


Moderna and Merck announce an investigational individualized neoantigen therapy
Clinical Trials | April 17, 2023

Moderna and Merck announce an investigational individualized neoantigen therapy

mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients


NS Pharma announces FDA clearance to initiate phase II study for an Exon 44 skipping candidate
Drug Approval | April 15, 2023

NS Pharma announces FDA clearance to initiate phase II study for an Exon 44 skipping candidate

Study efficacy measures will include the expression of dystrophin protein and motor function.


Chiesi Farmaceutici completes acquisition of Amryt Pharma
News | April 15, 2023

Chiesi Farmaceutici completes acquisition of Amryt Pharma

Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.


TransCure bioServices expands their team to lead the way in animal welfare
People | April 14, 2023

TransCure bioServices expands their team to lead the way in animal welfare

The new team members, Solenn Percelay and Noémie Spinelli, will support the organization’s commitment to excellence in humanized mouse model care and use


FDA accepts application for Merck’s Keytruda plus chemotherapy as first-line treatment for metastatic gastric
Drug Approval | April 14, 2023

FDA accepts application for Merck’s Keytruda plus chemotherapy as first-line treatment for metastatic gastric

Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression